{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:51:43Z","timestamp":1767135103551,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd014678","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T00:00:00Z","timestamp":1706054400000}}],"reference-count":140,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd014678.pub2","type":"journal-article","created":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T04:03:32Z","timestamp":1706069012000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis"],"prefix":"10.1002","volume":"2024","author":[{"given":"Samer","family":"Al Said","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, University Heart Center Freiburg Bad Krozingen; Faculty of Medicine, University of Freiburg; Freiburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Kaier","sequence":"additional","affiliation":[{"name":"Institute for Medical Biometry and Statistics; Faculty of Medicine and Medical Center, University of Freiburg; Freiburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wael","family":"Sumaya","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine; Dalhousie University, QE II Health Sciences Centre, Halifax Infirmary; Halifax Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dima","family":"Alsaid","sequence":"additional","affiliation":[{"name":"Institute for Evidence in Medicine, Medical Center \u2013 University of Freiburg; Faculty of Medicine, University of Freiburg; Freiburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Duerschmied","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Angiology, Haemostaseology and Medical Intensive Care; University Medical Centre Mannheim, Medical Faculty Mannheim, Heidelberg University; Mannheim Germany"},{"name":"European Center for AngioScience (ECAS) and German Center for Cardiovascular Research (DZHK) partner site Heidelberg\/Mannheim, Mannheim, Germany; Mannheim Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert F","family":"Storey","sequence":"additional","affiliation":[{"name":"Department of Infection, Immunity and Cardiovascular Disease; University of Sheffield; Sheffield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Michael","family":"Gibson","sequence":"additional","affiliation":[{"name":"Cardiology Division, Beth Israel Deaconess Medical Center; Harvard Medical School; Boston MA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Westermann","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Angiology, University Heart Center Freiburg Bad Krozingen; Faculty of Medicine, University of Freiburg; Freiburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samer","family":"Alabed","sequence":"additional","affiliation":[{"name":"Department of Infection, Immunity and Cardiovascular Disease; University of Sheffield; Sheffield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"issue":"22","key":"10.1002\/14651858.CD014678.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","article-title":"Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial","volume":"119","author":"Alexander","year":"2009","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0002|cit2","unstructured":"Safety study of apixaban in recent acute coronary syndrome clinicaltrials.gov\/show\/NCT00313300"},{"issue":"8","key":"10.1002\/14651858.CD014678.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014678.pub2-BIB0004|cit4","first-page":"335","article-title":"Apixaban after acute coronary syndrome in patients with heart failure: insights from the APPRAISE-2 trial","volume":"33","author":"Cornel","year":"2012","journal-title":"European Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD014678.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ahj.2014.12.022","article-title":"Anticoagulant therapy and outcomes in patients with prior or acute heart failure and acute coronary syndromes: insights from the APixaban for PRevention of Acute ISchemic Events 2 trial","volume":"169","author":"Cornel","year":"2015","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/JAHA.117.005490","article-title":"Reporting clinical end points and safety events in an acute coronary syndrome trial: results with integrated collection","volume":"6","author":"Guimaraes","year":"2017","journal-title":"Journal of the American Heart Association"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0007|cit7","first-page":"861","article-title":"Management and clinical consequences of major bleeding in high-risk patients following an acute coronary syndrome. Is aspirin the problem? Insights from the APPRAISE-2 trial","volume":"36 Suppl 1","author":"Hagstrom","year":"2015","journal-title":"European Heart Journal"},{"issue":"7","key":"10.1002\/14651858.CD014678.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2015.06.027","article-title":"Apixaban plus mono versus dual antiplatelet therapy in acute coronary syndromes: insights from the APPRAISE-2 trial","volume":"66","author":"Hess","year":"2015","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0009|cit9","first-page":"20","article-title":"Apixaban for prevention of acute ischemic events in patients with acute coronary syndromes","volume":"9 Suppl 2","author":"James","year":"2011","journal-title":"Journal of Thrombosis and Haemostasis"},{"issue":"18","key":"10.1002\/14651858.CD014678.pub2-BIB0010|cit10","first-page":"1475","article-title":"Characterising and predicting bleeding in high-risk patients with an acute coronary syndrome","volume":"101","author":"Khan","year":"2015","journal-title":"Heart (British Cardiac Society)"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0011|cit11","unstructured":"Phase III acute coronary syndrome (APPRAISE-2) clinicaltrials.gov\/show\/NCT00831441"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ahj.2019.05.004","article-title":"Clinical consequences of bleeding among individuals with a recent acute coronary syndrome: insights from the APPRAISE-2 trial","volume":"215","author":"Sharma","year":"2019","journal-title":"American Heart Journal"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD014678.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"A195","DOI":"10.1016\/S0735-1097(15)60195-4","article-title":"Apixaban following acute coronary syndromes among patients with prior stroke: insights from the app raise-2 trial","volume":"65","author":"Sherwood","year":"2015","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2017.09.020","article-title":"Apixaban following acute coronary syndromes in patients with prior stroke: insights from the APPRAISE-2 trial","volume":"197","author":"Sherwood","year":"2018","journal-title":"American Heart Journal"},{"issue":"9","key":"10.1002\/14651858.CD014678.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.amjcard.2018.07.032","article-title":"D-Dimer levels and effect of rivaroxaban on those levels and outcomes in patients with acute coronary syndrome (An ATLAS ACS-TIMI 46 Trial Substudy)","volume":"122","author":"AlKhalfan","year":"2018","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0016|cit16","unstructured":"Alkhalfan F Kerneis M Nafee T Yee Megan K Chi G Plotnikov A D-dimer levels and clinical outcomes in acute coronary syndrome patients: an ATLAS ACS TIMI 46 trial substudy Circulation 2018 138"},{"issue":"3","key":"10.1002\/14651858.CD014678.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11239-013-0968-y","article-title":"Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial","volume":"37","author":"Geller","year":"2014","journal-title":"Journal of Thrombosis and Thrombolysis"},{"issue":"9683","key":"10.1002\/14651858.CD014678.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(09)60738-8","article-title":"Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial","volume":"374","author":"Mega","year":"2009","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0019|cit19","unstructured":"Rivaroxaban in combination with aspirin alone or with aspirin and a thienopyridine in patients with acute coronary syndromes (The ATLAS ACS TIMI 46 Trial) clinicaltrials.gov\/show\/NCT00402597"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0020|cit20","unstructured":"An efficacy and safety study for rivaroxaban in patients with acute coronary syndrome clinicaltrials.gov\/show\/NCT00809965"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0021|cit21","unstructured":"Alkhalfan F Nafee T Yee M Chi GC Kalayci A Plotnikov A The association of white blood cell count and bleeding in acute coronary syndrome: an insight into the ATLAS ACS-TIMI 51 trial Circulation 2019 140 Suppl 1"},{"issue":"5","key":"10.1002\/14651858.CD014678.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.amjcard.2019.12.007","article-title":"Relation of white blood cell count to bleeding and ischemic events in patients with acute coronary syndrome (from the ATLAS ACS 2-TIMI 51 Trial)","volume":"125","author":"Alkhalfan","year":"2020","journal-title":"American Journal of Cardiology"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD014678.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"E1534","DOI":"10.1016\/S0735-1097(13)61534-X","article-title":"Bayesian net-clinical benefit analysis of rivaroxaban in patients with acute coronary syndromes","volume":"61","author":"Arora","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD014678.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.1016\/S0735-1097(13)60004-2","article-title":"Rivaroxaban reduces spontaneous and large myocardial infarctions: findings from the ATLAS ACS 2 \u2013 TIMI 51 trial","volume":"61","author":"Cavender","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD014678.pub2-BIB0025|cit25","first-page":"468","article-title":"The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 \u2013 TIMI 51 trial","volume":"4","author":"Cavender","year":"2015","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0026|cit26","unstructured":"A randomized, double-blind, placebo-controlled, event-driven multicenter study to evaluate the efficacy and safety of rivaroxaban in subjects with a recent acute coronary syndrome. The ATLAS ACS 2 TIMI 51 Trial www.clinicaltrialsregister.eu\/ctr-search\/search?query=2008-002708-25 2009"},{"issue":"126","key":"10.1002\/14651858.CD014678.pub2-BIB0027|cit27","first-page":"A13152","article-title":"A net clinical outcome analysis comparing fatal or irreversible ischemic and bleeding events in ATLAS ACS 2 \u2013 TIMI 51, abstract 13152","volume":"2012","author":"Gibson","year":"2018","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD014678.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jacc.2013.03.041","article-title":"Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51","volume":"62","author":"Gibson","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD014678.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jacc.2018.04.055","article-title":"Fatal or irreversible bleeding and ischemic events with rivaroxaban in acute coronary syndrome","volume":"72","author":"Gibson","year":"2018","journal-title":"Journal of the American College of Cardiology"},{"issue":"21","key":"10.1002\/14651858.CD014678.pub2-BIB0030|cit30","first-page":"2367","article-title":"Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS ACS 2-TIMI 51) trial: a randomized, double-blind, placebo controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome","volume":"124","author":"Gibson","year":"2011","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD014678.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ahj.2011.01.026","article-title":"Rationale and design of the Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome","volume":"161","author":"Gibson","year":"2011","journal-title":"American Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD014678.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"e009451","DOI":"10.1161\/JAHA.118.009451","article-title":"Safety and efficacy of rivaroxaban when added to aspirin monotherapy among stabilized post-acute coronary syndrome patients: a pooled analysis study of ATLAS ACS-TIMI 46 and ATLAS ACS 2-TIMI 51","volume":"8","author":"Gibson","year":"2019","journal-title":"Journal of the American Heart Association"},{"issue":"1","key":"10.1002\/14651858.CD014678.pub2-BIB0033|cit33","first-page":"140","article-title":"Anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate","volume":"33","author":"Gibson","year":"2012","journal-title":"European Heart Journal"},{"issue":"11","key":"10.1002\/14651858.CD014678.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/j.amjcard.2018.08.034","article-title":"Usefulness of rivaroxaban for secondary prevention of acute coronary syndrome in patients with history of congestive heart failure (from the ATLAS-ACS-2 TIMI-51 Trial)","volume":"122","author":"Korjian","year":"2018","journal-title":"American Journal of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD014678.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/2048872617745003","article-title":"Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: insights from the ATLAS ACS 2-TIMI 51 trial","volume":"8","author":"Korjian","year":"2019","journal-title":"European Heart Journal. Acute Cardiovascular Care"},{"issue":"9","key":"10.1002\/14651858.CD014678.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.jacc.2013.05.024","article-title":"The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome ACS 2-Thrombolysis In Myocardial Infarction 51)","volume":"62","author":"Krantz","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014678.pub2-BIB0037|cit37","first-page":"992","article-title":"Rivaroxaban in patients after an acute coronary syndrome with cardiac biomarker elevation: insights from the ATLAS ACS 2-TIMI 51 trial","volume":"35","author":"Mega","year":"2014","journal-title":"European Heart Journal"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD014678.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"E4","DOI":"10.1016\/S0735-1097(13)60005-4","article-title":"Rivaroxaban in the setting of continued dual antiplatelet therapy: findings from the atlas ACS 2-TIMI 51 trial","volume":"61","author":"Mega","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD014678.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"245","DOI":"10.20996\/1819-6446-2014-10-2-245-252","article-title":"Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction. Results from the ATLAS-ACS-2-TIMI-51 trial","volume":"10","author":"Mega","year":"2014","journal-title":"Rational Pharmacotherapy in Cardiology"},{"issue":"18","key":"10.1002\/14651858.CD014678.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.jacc.2013.01.066","article-title":"Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction: results from the ATLAS ACS-2-TIMI-51 trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis In Myocardial Infarction-51)","volume":"61","author":"Mega","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD014678.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"21 Suppl 1","key":"10.1002\/14651858.CD014678.pub2-BIB0042|cit42","first-page":"A16014","article-title":"Evaluation of cardiac events in ATLAS ACS 2-TIMI 51","volume":"126","author":"Mega","year":"2012","journal-title":"Circulation"},{"issue":"4","key":"10.1002\/14651858.CD014678.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.amjcard.2013.04.011","article-title":"Comparison of the efficacy and safety of two rivaroxaban doses in acute coronary syndrome (from ATLAS ACS 2-TIMI 51)","volume":"112","author":"Mega","year":"2013","journal-title":"American Journal of Cardiology"},{"issue":"10","key":"10.1002\/14651858.CD014678.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"JC5","DOI":"10.7326\/0003-4819-156-10-201205150-02003","article-title":"Low-Dose rivaroxaban reduced mortality in patients with a recent acute coronary syndrome","volume":"156","author":"Mega","year":"2012","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0045|cit45","first-page":"22 Suppl 1","article-title":"The efficacy and safety of low-dose rivaroxaban with or without a proton pump inhibitor: insights from the atlas ACS 2-TIMI 51 trial","volume":"128","author":"O'Donoghue","year":"2013","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0046|cit46","first-page":"3 Suppl 1","article-title":"Economic burden of mortality and cardiovascular events among patients with acute coronary syndromes in a commercial health plan","volume":"6","author":"Ogden","year":"2013","journal-title":"Circulation: Cardiovascular Quality and Outcomes"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"175394471986364","DOI":"10.1177\/1753944719863641","article-title":"Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome","volume":"13","author":"Zhang","year":"2019","journal-title":"Therapeutic Advances in Cardiovascular Disease"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0048|cit48","unstructured":"A study to compare the safety of rivaroxaban versus acetylsalicylic acid in addition to either clopidogrel or ticagrelor therapy in participants with acute coronary syndrome clinicaltrials.gov\/show\/NCT02293395"},{"issue":"10081","key":"10.1002\/14651858.CD014678.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/S0140-6736(17)30751-1","article-title":"Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial","volume":"389","author":"Ohman","year":"2017","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.ahj.2016.01.004","article-title":"A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: the design of the GEMINI-ACS-1 phase II study","volume":"174","author":"Povsic","year":"2016","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0051|cit51","unstructured":"RE-DEEM dose finding study for dabigatran etexilate in patients with acute coronary syndrome clinicaltrials.gov\/show\/NCT00621855"},{"issue":"22","key":"10.1002\/14651858.CD014678.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"European Heart Journal"},{"issue":"21","key":"10.1002\/14651858.CD014678.pub2-BIB0053|cit53","first-page":"2160","article-title":"Randomised dabigatran etexilate dose finding study in patients with acute coronary syndromes post index event with additional risk factors for cardiovascular complications also receiving aspirin and clopidogrel (RE-DEEM)","volume":"120","author":"Oldgren","year":"2010","journal-title":"Circulation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD014678.pub2-BIB0054|cit54","first-page":"4026","article-title":"The use of direct oral anti-coagulations (DOACs) compared to vitamin K antagonist in patients with left ventricular thrombus after acute myocardial infarction","volume":"40","author":"Alizadeh","year":"2019","journal-title":"European Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD014678.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1182\/bloodadvances.2017013573","article-title":"Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction","volume":"2","author":"Borst","year":"2018","journal-title":"Blood Advances"},{"issue":"10137","key":"10.1002\/14651858.CD014678.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1016\/S0140-6736(18)30832-8","article-title":"Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial","volume":"391","author":"Devereaux","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD014678.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.cjca.2018.01.020","article-title":"Design of a randomized placebo-controlled trial to assess dabigatran and omeprazole in patients with myocardial injury after noncardiac surgery (MANAGE)","volume":"34","author":"Duceppe","year":"2018","journal-title":"Canadian Journal of Cardiology"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0058|cit58","unstructured":"Rivaroxaban for the prevention of major cardiovascular events in coronary or peripheral artery disease www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2012-004180-43-CZ 2013"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0059|cit59","unstructured":"A study to assess the effectiveness and safety of rivaroxaban in reducing the risk of death, myocardial infarction or stroke in participants with heart failure and coronary artery disease following an episode of decompensated heart failure www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2013-000046-19-BG 2013"},{"issue":"16 Suppl 1","key":"10.1002\/14651858.CD014678.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"C158","DOI":"10.1016\/j.jacc.2015.06.605","article-title":"Risk of hemorrhagic and ischemic stroke for dual antiplatelet therapy and new generation oral anticoagulants in patients with acute coronary syndrome","volume":"66","author":"Gao","year":"2015","journal-title":"Journal of the American College of Cardiology"},{"issue":"25","key":"10.1002\/14651858.CD014678.pub2-BIB0061|cit61","first-page":"e761","article-title":"Effects of rivaroxaban on thrombotic events in heart failure patients with coronary disease and sinus rhythm","volume":"138","author":"Greenberg","year":"2018","journal-title":"Circulation"},{"issue":"11","key":"10.1002\/14651858.CD014678.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.cardfail.2018.11.006","article-title":"A randomized study comparing rivaroxaban with placebo in subjects with heart failure and significant coronary artery disease following an episode of decompensated heart failure: the COMMANDER HF study","volume":"24","author":"Greenberg","year":"2018","journal-title":"Journal of Cardiac Failure"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0063|cit63","first-page":"Suppl 1","article-title":"Percutaneous coronary intervention and antiplatelet therapy on apixaban or warfarin: insights from the ARISTOTLE trial","volume":"134","author":"Kopin","year":"2016","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ahj.2018.08.007","article-title":"Randomized trial of rivaroxaban versus warfarin in the evaluation of progression of coronary atherosclerosis","volume":"206","author":"Lee","year":"2018","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0065|cit65","unstructured":"Preventing cardiac complication of COVID-19 disease with early acute coronary syndrome therapy: a randomised controlled trial clinicaltrials.gov\/show\/NCT04333407"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0066|cit66","unstructured":"Dual therapy with dabigatran\/ticagrelor versus dual therapy with dabigatran\/clopidogrel in ACS patients with indication for NOAC undergoing PCI clinicaltrials.gov\/show\/NCT04688723"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0067|cit67","unstructured":"Rivaroxaban or aspirin in patients with CHD & GD undergoing PCI clinicaltrials.gov\/show\/NCT04805710"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0068|cit68","unstructured":"Rivaroxaban in type 2 myocardial infarctions clinicaltrials.gov\/show\/NCT04838808"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0069|cit69","unstructured":"Management of myocardial injury after noncardiac surgery trial clinicaltrials.gov\/show\/NCT01661101"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0070|cit70","first-page":"Suppl 1","article-title":"Do randomized clinical trial selection criteria reflect real-life levels of risk in acute myocardial infarction survivors? the compass trial in light of the FAST-MI 2005-2010-2015 registries","volume":"138","author":"Schiele","year":"2018","journal-title":"Circulation"},{"issue":"7","key":"10.1002\/14651858.CD014678.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/ejhf.266","article-title":"Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial","volume":"17","author":"Zannad","year":"2015","journal-title":"European Journal of Heart Failure"},{"issue":"14","key":"10.1002\/14651858.CD014678.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1056\/NEJMoa1808848","article-title":"Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease","volume":"379","author":"Zannad","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0073|cit73","unstructured":"Can very low dose rivaroxaban in addition to dual antiplatelet therapy (DAPT) improve thrombotic status in acute coronary syndrome (ACS) ACS (VaLiDate-R) clinicaltrials.gov\/show\/NCT03775746"},{"issue":"4","key":"10.1002\/14651858.CD014678.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1055\/s-0038-1673412","article-title":"Anticoagulation in Atherosclerotic Disease","volume":"38","author":"Al Said","year":"2018","journal-title":"Hamostaseologie"},{"issue":"5","key":"10.1002\/14651858.CD014678.pub2-BIB0075|cit75","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD014678","article-title":"Non-vitamin-K-antagonist oral anticoagulants (NOACs) after acute myocardial infarction: a network meta-analysis","author":"Al Said","year":"2021","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"22","key":"10.1002\/14651858.CD014678.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1161\/CIRCULATIONAHA.108.832139","article-title":"Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial","volume":"119","author":"Alexander","year":"2009","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD014678.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"24","key":"10.1002\/14651858.CD014678.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1016\/j.jacc.2014.09.017","article-title":"2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"64","author":"Amsterdam","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"62S","DOI":"10.1016\/S0735-1097(02)02776-6","article-title":"Oral anticoagulants in patients with coronary artery disease","volume":"41","author":"Anand","year":"2003","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/eurheartj\/ehi485","article-title":"Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients","volume":"27","author":"Andreotti","year":"2006","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1182\/asheducation-2013.1.464","article-title":"Pros and cons of new oral anticoagulants","volume":"2013","author":"Bauer","year":"2013","journal-title":"Hematology"},{"issue":"19","key":"10.1002\/14651858.CD014678.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1056\/NEJMoa1500857","article-title":"Long-term use of ticagrelor in patients with prior myocardial infarction","volume":"372","author":"Bonaca","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0083|cit83","doi-asserted-by":"publisher","first-page":"m3907","DOI":"10.1136\/bmj.m3907","article-title":"GRADE approach to drawing conclusions from a network meta-analysis using a partially contextualised framework","volume":"371","author":"Brignardello-Petersen","year":"2020","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0084|cit84","unstructured":"Chaimani A Caldwell DM Li T Higgins JP Salanti G Chapter 11: Undertaking network meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v.6.3"},{"issue":"1","key":"10.1002\/14651858.CD014678.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1161\/01.CIR.76.1.142","article-title":"Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge","volume":"76","author":"Chesebro","year":"1987","journal-title":"Circulation"},{"issue":"3","key":"10.1002\/14651858.CD014678.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamacardio.2017.5306","article-title":"Direct oral anticoagulants in addition to antiplatelet therapy for secondary prevention after acute coronary syndromes: a systematic review and meta-analysis","volume":"3","author":"Chiarito","year":"2018","journal-title":"JAMA Cardiology"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0087|cit87","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1998"},{"issue":"14","key":"10.1002\/14651858.CD014678.pub2-BIB0088|cit88","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Thiele","year":"2021","journal-title":"European Heart Journal"},{"issue":"12","key":"10.1002\/14651858.CD014678.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/ajh.25475","article-title":"Reversal of direct oral anticoagulants: guidance from the Anticoagulation Forum","volume":"94","author":"Cuker","year":"2019","journal-title":"American Journal of Hematology"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1161\/CIRCULATIONAHA.106.685313","article-title":"Clinical end points in coronary stent trials: a case for standardized definitions","volume":"115","author":"Cutlip","year":"2007","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0092|cit92","unstructured":"Deeks JJ Higgins JPT Altman DG Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v.6.3"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1146\/annurev-med-062209-095159","article-title":"Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism","volume":"62","author":"Eriksson","year":"2011","journal-title":"Annual Review of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD014678.pub2-BIB0094|cit94","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1093\/eurheartj\/ehy656","article-title":"Impaired endogenous fibrinolysis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention is a predictor of recurrent cardiovascular events: the RISK PPCI study","volume":"40","author":"Farag","year":"2019","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD014678.pub2-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.ahj.2014.11.002","article-title":"Balancing the risks of bleeding and stent thrombosis: a decision analytic model to compare durations of dual antiplatelet therapy after drug-eluting stents","volume":"169","author":"Garg","year":"2015","journal-title":"American Heart Journal"},{"issue":"5","key":"10.1002\/14651858.CD014678.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ahj.2011.01.026","article-title":"Rationale and design of the anti-Xa therapy to lower cardiovascular events in addition to standard therapy in subjects with acute coronary syndrome-thrombolysis in myocardial infarction 51 (ATLAS-ACS 2 TIMI 51) trial: a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rivaroxaban in subjects with acute coronary syndrome","volume":"161","author":"Gibson","year":"2011","journal-title":"American Heart Journal"},{"issue":"22","key":"10.1002\/14651858.CD014678.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"5","key":"10.1002\/14651858.CD014678.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1160\/TH14-12-1080","article-title":"A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran","volume":"113","author":"Glund","year":"2015","journal-title":"Thrombosis and Haemostasis"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0099|cit99","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2015"},{"issue":"11","key":"10.1002\/14651858.CD014678.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0101|cit101","unstructured":"Higgins JP Altman DG Sterne JA Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017 Available from training.cochrane.org\/handbook\/archive\/v5.2"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1056\/NEJMoa020496","article-title":"Warfarin, aspirin, or both after myocardial infarction","volume":"347","author":"Hurlen","year":"2002","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD014678.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","article-title":"2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)","volume":"39","author":"Ibanez","year":"2018","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1002\/sim.5453","article-title":"Quantifying the impact of between-study heterogeneity in multivariate meta-analyses","volume":"31","author":"Jackson","year":"2012","journal-title":"Statistics in Medicine"},{"issue":"10159","key":"10.1002\/14651858.CD014678.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1016\/S0140-6736(18)32279-7","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017","volume":"392","author":"James","year":"2018","journal-title":"Lancet"},{"issue":"1","key":"10.1002\/14651858.CD014678.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s12872-018-0859-4","article-title":"Predictors of high-cost hospitalization in the treatment of acute coronary syndrome in Asia: findings from EPICOR Asia","volume":"18","author":"Jan","year":"2018","journal-title":"BMC Cardiovascular Disorders"},{"issue":"19","key":"10.1002\/14651858.CD014678.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1093\/eurheartj\/ehu505","article-title":"Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective","volume":"36","author":"Jernberg","year":"2015","journal-title":"European Heart Journal"},{"issue":"3","key":"10.1002\/14651858.CD014678.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.amjcard.2017.10.035","article-title":"Meta-analysis of the safety and efficacy of the oral anticoagulant agents (apixaban, rivaroxaban, dabigatran) in patients with acute coronary syndrome","volume":"121","author":"Khan","year":"2018","journal-title":"American Journal of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD014678.pub2-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s12471-018-1113-5","article-title":"Optimal duration of dual antiplatelet therapy for coronary artery disease","volume":"26","author":"Kikkert","year":"2018","journal-title":"Netherlands Heart Journal"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2288-13-35","article-title":"A graphical tool for locating inconsistency in network meta-analyses","volume":"13","author":"Krahn","year":"2013","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0111|cit111","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Marshall C Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v.6.3"},{"issue":"23","key":"10.1002\/14651858.CD014678.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJM199812033392303","article-title":"A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting","volume":"339","author":"Leon","year":"1998","journal-title":"New England Journal of Medicine"},{"key":"#cr-split#-10.1002\/14651858.CD014678.pub2-BIB0113|cit113.1","unstructured":"Liang L Moore B Soni A National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2017: Statistical Brief #261"},{"key":"#cr-split#-10.1002\/14651858.CD014678.pub2-BIB0113|cit113.2","unstructured":"July 2020 www.hcup-us.ahrq.gov\/reports\/statbriefs\/sb261-Most-Expensive-Hospital-Conditions-2017.jsp"},{"issue":"1","key":"10.1002\/14651858.CD014678.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD014678.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1161\/01.CIR.90.1.61","article-title":"Persistent activation of coagulation mechanism in unstable angina and myocardial infarction","volume":"90","author":"Merlini","year":"1994","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0116|cit116","unstructured":"Rivaroxaban for prevention adverse outcomes after acute management of acute coronary syndrome www.nice.org.uk\/guidance\/ta335\/resources\/rivaroxaban-for-preventing-adverse-outcomes-after-acute-management-of-acute-coronary-syndrome-82602549055429"},{"issue":"4","key":"10.1002\/14651858.CD014678.pub2-BIB0117|cit117","doi-asserted-by":"publisher","first-page":"e362","DOI":"10.1161\/CIR.0b013e3182742cf6","article-title":"American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"127","author":"O'Gara","year":"2013","journal-title":"Circulation"},{"issue":"22","key":"10.1002\/14651858.CD014678.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"European Heart Journal"},{"issue":"22","key":"10.1002\/14651858.CD014678.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/eurheartj\/eht049","article-title":"New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis","volume":"34","author":"Oldgren","year":"2013","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0120|cit120","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"10","key":"10.1002\/14651858.CD014678.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD014678.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","author":"Pollack","year":"2015","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0123|cit123","unstructured":"Review Manager 5 (RevMan 5) Nordic Cochrane Centre, The Cochrane Collaboration 2020"},{"issue":"3","key":"10.1002\/14651858.CD014678.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/eurheartj\/ehv320","article-title":"2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC)","volume":"37","author":"Roffi","year":"2016","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"241","DOI":"10.7326\/0003-4819-143-4-200508160-00005","article-title":"Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit","volume":"143","author":"Rothberg","year":"2005","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD014678.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/jrsm.1058","article-title":"Network meta-analysis, electrical networks and graph theory","volume":"3","author":"R\u00fccker","year":"2012","journal-title":"Research Synthesis Methods"},{"issue":"25","key":"10.1002\/14651858.CD014678.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1002\/sim.6236","article-title":"Reduce dimension or reduce weights? Comparing two approaches to multi-arm studies in network meta-analysis","volume":"33","author":"R\u00fccker","year":"2014","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12874-015-0060-8","article-title":"Ranking treatments in frequentist network meta-analysis works without resampling methods","volume":"15","author":"R\u00fccker","year":"2015","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0129|cit129","unstructured":"R\u00fccker G Schwarzer G Krahn U K\u00f6nig J netmeta: Network Meta-Analysis using Frequentist Methods cran.r-project.org\/web\/packages\/netmeta"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1016\/j.jacc.2010.01.033","article-title":"Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction","volume":"55","author":"Saraf","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0131|cit131","unstructured":"Sch\u00fcnemann HJ Higgins JPT Vist GE Glasziou P Akl EA Skoetz N Guyatt GH Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.3 (updated February 2022). Cochrane, 2022 Available from training.cochrane.org\/handbook\/archive\/v.6.3"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/eurheartj\/ehy013","article-title":"Fibrin clot properties independently predict adverse clinical outcome following acute coronary syndrome: a PLATO substudy","volume":"39","author":"Sumaya","year":"2018","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1055\/s-0038-1657768","article-title":"Pharmacodynamic effects of a 6-hour regimen of enoxaparin in patients undergoing primary percutaneous coronary intervention (PENNY PCI Study)","volume":"118","author":"Sumaya","year":"2018","journal-title":"Thrombosis and Haemostasis"},{"issue":"3","key":"10.1002\/14651858.CD014678.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1055\/s-0039-1701011","article-title":"Impaired fibrinolysis predicts adverse outcome in acute coronary syndrome patients with diabetes: a PLATO sub-study","volume":"120","author":"Sumaya","year":"2020","journal-title":"Thrombosis and Haemostasis"},{"issue":"3","key":"10.1002\/14651858.CD014678.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli","year":"2017","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0140-6736(02)09409-6","article-title":"Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) research group. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial","volume":"360","author":"Es","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1016\/j.thromres.2012.11.029","article-title":"Whole blood clots are more resistant to lysis than plasma clots \u2013 greater efficacy of rivaroxaban","volume":"131","author":"Varin","year":"2013","journal-title":"Thrombosis Research"},{"issue":"10053","key":"10.1002\/14651858.CD014678.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0140-6736(16)31678-6","article-title":"Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990\u20132015: a systematic analysis for the Global Burden of Disease Study 2015","volume":"388","author":"Vos","year":"2016","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD014678.pub2-BIB0139|cit139","unstructured":"Wilkins E Wilson L Wickramasinghe K Bhatnagar P Leal J Luengo-Fernandez R European Cardiovascular Disease Statistics 2017 European Heart Network, Brussels"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T07:33:39Z","timestamp":1737099219000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD014678.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Heart Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":140,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd014678.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,24]]}}}